CVS Health Corp. (NYSE:CVS)

The period under review demonstrates significant fluctuations in economic profit. Net operating profit after taxes (NOPAT) exhibited volatility, beginning at US$9,067 million, decreasing substantially to US$3,871 million, then recovering to US$9,523 million before declining again to US$5,319 million. Concurrently, the cost of capital increased from 7.68% to 9.03% over the first three years, then decreased to 8.07% by the final year. Invested capital generally decreased from US$136,669 million to US$123,703 million, before increasing to US$134,694 million and subsequently decreasing to US$131,642 million.

Economic Profit Trend

Economic profit consistently remained negative throughout the observed period. The largest negative economic profit occurred in 2022, reaching US$-7,297 million. While 2021 showed a negative economic profit of US$-2,472 million, it was less severe than in 2020, 2022, 2023, and 2024. The economic profit in 2023 was US$-1,788 million, representing a relative improvement compared to 2022, but it deteriorated again in 2024 to US$-5,299 million.

Relationship between NOPAT and Economic Profit

The fluctuations in NOPAT appear to directly influence economic profit. The substantial decline in NOPAT in 2022 coincided with the most significant negative economic profit for the period. The recovery in NOPAT in 2023 contributed to a less negative economic profit, although the cost of capital remained relatively high. The subsequent decline in NOPAT in 2024 resulted in a worsening of the economic profit.

Impact of Cost of Capital

The increasing cost of capital between 2020 and 2022 likely exacerbated the negative economic profit during those years. Although the cost of capital decreased in the final two years, it did not fully offset the impact of fluctuations in NOPAT. The interplay between NOPAT and the cost of capital is a key driver of the observed economic profit performance.

Invested Capital Considerations

Changes in invested capital appear to have a less direct correlation with economic profit compared to NOPAT and the cost of capital. While invested capital decreased during the period of increasing cost of capital, the primary driver of the negative economic profit appears to be the insufficient NOPAT to cover the cost of the invested capital.

Net income attributable to CVS Health

The net income exhibited fluctuations over the five-year period. Starting at $7,179 million in 2020, there was an increase to $7,910 million in 2021, indicating growth. However, in 2022, net income notably declined to $4,149 million, reflecting a significant drop. This was followed by a rebound in 2023, reaching $8,344 million, which represents the highest point in the period. In 2024, net income once again decreased to $4,614 million, showing volatility and an overall irregular pattern in earnings.

Net operating profit after taxes (NOPAT)

NOPAT followed a pattern broadly similar to net income but with less pronounced volatility. It began at $9,067 million in 2020 and slightly increased to $9,170 million in 2021. In 2022, there was a sharp decline to $3,871 million, mirroring the net income decline of that year. The subsequent year, 2023, saw a recovery to $9,523 million, the highest level observed in this timeframe. By 2024, NOPAT decreased again to $5,319 million. This trend suggests that while operating profitability is subject to cyclical pressures, it remains relatively strong when it rebounds.

Insights

The data reveals substantial volatility in both net income and NOPAT with synchronous fluctuations particularly pronounced in 2022 and 2024. These troughs could indicate periods of operational or market challenges impacting profitability. Despite these downturns, the company demonstrated resilience with robust recoveries in 2023, suggesting effective management responses or favorable market conditions during that year. The gap between net income and NOPAT levels also suggests that non-operating factors or tax impacts may play a role in overall profitability fluctuations. The irregular pattern underscores the importance of closely monitoring operational efficiency and external factors influencing financial performance.

Income Tax Provision

The income tax provision exhibited a fluctuating trend over the years observed. It decreased from $2,569 million in 2020 to $2,522 million in 2021, indicating a slight reduction. This was followed by a more significant decline to $1,463 million in 2022. However, in 2023, the provision increased sharply to $2,805 million, before decreasing again to $1,562 million in 2024. Overall, the income tax provision shows variability with notable peaks and troughs during the five-year period.

Cash Operating Taxes

Cash operating taxes showed a moderate decline from $3,769 million in 2020 to $3,407 million in 2021. In 2022, there was an increase to $4,013 million, marking the highest point in the period reviewed. Subsequently, the amount slightly decreased to $3,965 million in 2023, followed by a significant drop to $2,464 million in 2024. This pattern indicates some volatility with an overall downward movement towards the end of the period.

Comparative Insights

Both income tax provision and cash operating taxes demonstrate considerable year-to-year fluctuations. Cash operating taxes consistently remained higher than the income tax provision across all years. The disparity between the two measures also varied, with the smallest gap occurring in 2024. This suggests possible changes in tax planning, timing differences, or cash tax payments relative to accounting tax expense over the evaluated periods.

Total reported debt & leases

The total reported debt and leases decreased from 85,042 million US dollars at the end of 2020 to 70,732 million US dollars by the end of 2022. This decline indicates a reduction in leverage during this period. However, starting from 2023, there is a notable increase, rising to 79,385 million US dollars and further to 82,920 million US dollars by the end of 2024, suggesting renewed borrowing or leasing commitments.

Total CVS Health shareholders’ equity

Shareholders’ equity showed a rising trend from 69,389 million US dollars in 2020, peaking at 75,075 million in 2021. Following this peak, equity experienced a slight pullback to 71,015 million in 2022 but recovered to 76,461 million in 2023. By 2024, it marginally declined again to 75,560 million US dollars. Overall, equity levels remained relatively stable with moderate fluctuations around the mid-70 billion range in the most recent years.

Invested capital

Invested capital declined steadily from 136,669 million US dollars in 2020 to 123,703 million in 2022, reflecting overall reductions in capital employed. This trend reversed in 2023 with an increase to 134,694 million followed by a slight decrease to 131,642 million in 2024. The pattern suggests a cycle of divestments or asset optimization up to 2022 and subsequent reinvestment or capital expansion over the following years, indicating adjustments in capital structure or operational focus.

The economic spread ratio exhibited considerable fluctuation between 2020 and 2024. Initially negative, the ratio demonstrated a significant decline through 2022 before partially recovering in subsequent periods, though remaining negative throughout the analyzed timeframe. Economic profit consistently registered as a negative value across all years, indicating the company’s returns did not exceed its cost of capital.

Economic Spread Ratio

The economic spread ratio decreased from -1.04% in 2020 to -1.89% in 2021, suggesting a widening gap between the company’s return on invested capital and its cost of capital. This decline accelerated substantially in 2022, reaching -5.90%, representing the most significant negative spread observed during the period. A partial recovery occurred in 2023, with the ratio improving to -1.33%, followed by a further, though less dramatic, deterioration to -4.03% in 2024. The overall trend indicates a struggle to generate returns exceeding the cost of capital, with 2022 representing a particularly challenging year.

Economic Profit

Economic profit moved from -1,428 million in 2020 to -2,472 million in 2021, mirroring the worsening economic spread. The largest absolute value of economic profit loss occurred in 2022 at -7,297 million, aligning with the most negative economic spread ratio. A substantial improvement was seen in 2023, with economic profit decreasing to -1,788 million. However, this improvement was not sustained, as economic profit decreased again to -5,299 million in 2024. The consistent negative values suggest that, despite substantial invested capital, the company has not consistently generated sufficient returns to cover its cost of capital.

Invested Capital

Invested capital decreased from 136,669 million in 2020 to 130,882 million in 2021, and continued to decline to 123,703 million in 2022. A notable increase occurred in 2023, rising to 134,694 million, before decreasing slightly to 131,642 million in 2024. While the invested capital experienced fluctuations, it remained at a substantial level throughout the period. The changes in invested capital do not appear to directly correlate with the fluctuations in economic profit or the economic spread ratio, suggesting factors beyond capital deployment are significantly influencing profitability.

In summary, the period under review was characterized by negative economic profit and a generally negative economic spread ratio. While some improvement was observed in 2023, the overall trend suggests ongoing challenges in generating returns that adequately compensate for the cost of capital. The fluctuations in invested capital do not fully explain the observed performance, indicating the need for further investigation into the underlying drivers of profitability.

The economic profit margin exhibited significant fluctuations between 2020 and 2024. Initially negative, the margin deteriorated substantially over the period before showing some signs of improvement, though remaining negative overall. A detailed examination of the trends is presented below.

Economic Profit Margin Trend

In 2020, the economic profit margin stood at -0.53%. This metric then declined considerably to -0.85% in 2021. The most substantial decrease occurred between 2021 and 2022, with the margin reaching -2.27%. A notable improvement was observed in 2023, with the margin increasing to -0.50%. However, this positive trend was not sustained, as the margin decreased again in 2024 to -1.43%.

The economic profit itself consistently remained negative throughout the analyzed period. While the economic profit margin and economic profit values moved in the same direction, the magnitude of the economic profit fluctuations was considerably larger than the margin fluctuations. This suggests that changes in revenues played a significant role in the observed trends.

Revenue Correlation

Revenues from customers demonstrated a consistent upward trend, increasing from US$267,908 million in 2020 to US$370,656 million in 2024. Despite this revenue growth, the economic profit margin remained negative, indicating that the cost of capital consistently exceeded the returns generated from revenue. The largest decline in the economic profit margin in 2022 coincided with the largest absolute increase in economic profit loss, despite a substantial increase in revenues that year.

The observed pattern suggests that while the company has been successful in growing its revenue base, it has struggled to generate returns exceeding its cost of capital. The improvement in the economic profit margin in 2023, despite continued negative economic profit, indicates a potential, albeit limited, increase in efficiency or a decrease in the cost of capital during that year. However, the subsequent decline in 2024 suggests this improvement was not sustained.